The most interesting word in MCS Health's description of itself is not health. It is independent. Health tells you the beat. Independence tells you the business. For four decades, this New Jersey communications agency has chosen the awkward middle ground between a local boutique and a global holding company: small enough for senior people to remain close to the work, specialized enough to understand a clinical endpoint, and lately connected enough to execute in more than 50 countries.
The formula sounds neat now. It did not arrive neat. MCS began in 1985, co-founded by Calep “Joe” Boyd III, a former crime and court reporter who had crossed into pharmaceutical public relations at Ciba-Geigy. The reporter's reflex survived the career change. Find the consequential fact. Translate it without flattening it. Give the audience a reason to care.
MCS says its assignments have touched the eradication of smallpox, the first cardiovascular mega-trials, the mapping of the human genome, a blockbuster anticoagulant, early direct-to-consumer healthcare marketing and, more recently, mRNA. That list spans several eras of medicine and nearly every era of modern media. The continuity is not the channel. It is the need to make difficult science legible without making it silly.
The product is a change of mind
Public relations can look like a pile of outputs: a press release here, an executive interview there, some social posts to keep the calendar from appearing abandoned. MCS frames the job one level higher. A patient decides to ask about care. A physician considers a different approach. An advocate lends credibility. A health system becomes more intelligible to its community. The actual product is movement.
That is why its menu appears almost comically broad for a compact firm. MCS handles brand communications, disease awareness, clinical and regulatory data, digital and social work, creative design, celebrities and influencers, clinical-trial recruitment and custom analytics. A racing partnership for the Lupus Research Alliance sits on the same continuum as the explanation of a study result. Different messenger, same behavioral problem: who needs to hear what, from whom, and what should happen next?
The customers follow the complexity. Pharmaceutical and biotech companies hire the firm around products, pipelines and regulatory milestones. Medtech and digital-health companies need adoption stories. Health systems and payers need reputation and community trust. Clinical-research organizations need participants. Nonprofits and advocacy groups need attention that produces more than a momentary spike. The publicly named roster has included Bayer, Idorsia, Insmed, Johnson & Johnson Innovative Medicine, Mayne Pharma, PhotoCure, RWJBarnabas Health and the Lupus Research Alliance. Earlier relationships include Genentech and Horizon Blue Cross Blue Shield of New Jersey.
The budget belongs to the client
Eliot Harrison joined MCS in 2004 and became president in 2017. His governing idea is less about messaging than posture: behave like part of the client's operating team, not a visiting vendor. In practice that means senior people stay involved, scientific understanding is not handed off after the pitch, and the agency is willing to recommend another partner when that partner is better suited to the problem.
“It's not our budget, it's our clients.”Eliot Harrison, on choosing the best solution rather than defending agency turf
That sentence is both generous and commercially sharp. An agency that occasionally gives revenue away may earn a more durable kind of account. Worldwide Partners says MCS has held relationships lasting decades with Johnson & Johnson and Genentech. The alternative is familiar: competing departments divide a brief according to their own utilization targets, and the client receives a very integrated invoice.
MCS makes money in the ordinary agency fashion - retainers and project fees for counsel and execution. It does not publish a rate card, and no reliable public figure says what a typical engagement costs. The useful public number is company-level: trade publication O'Dwyer's reported $4.3 million in 2025 net fees. That is not a client price. It is a window into the scale of the operating business.
A down year, drawn to scale
*Approximation implied by the reported 6.4% decline. Net fees, not gross billings or client pricing.
The first crack was useful
In 2025, MCS's net fees fell 6.4 percent. The wider healthcare PR sector also contracted, but a decline has a clarifying effect that growth rarely provides. Clients were asking for more sophisticated scientific stories, more precise identification of influential voices and a credible answer to the way AI was changing discovery. They also wanted global capability without being trapped inside a fixed network.
That changed the agency's posture. MCS strengthened AI-enabled analytics and data intelligence, refined how it maps influence, added senior capability across operations, digital, consumer and integrated communications, and joined Worldwide Partners in August 2025. The network now gives it access to 115 offices in more than 50 countries, including more than 1,000 healthcare and pharma-biotech specialists across 20-plus countries.
The distinction matters. MCS did not buy offices, merge into a holding company or pretend that every market needs a copy of the Morristown operation. It connected to independent firms that can be assembled around the problem. Scale became a variable cost and a collaboration choice, not an org chart.
A playbook worth stealing carefully
There are three portable ideas here. First, narrow expertise can make a small company feel larger because it reduces the client's need to translate. Second, senior attention is a product, not merely a staffing promise. Third, a network is most useful when members can admit who is best for a job.
- Choose a domain where accumulated judgment compounds.
- Organize services around the customer's desired action, not your departments.
- Keep the relationship senior-led after the pitch.
- Partner for geography and specialist gaps instead of owning every capability.
- Measure the behavior that changed, not the volume of material produced.
The model has boundaries. A buyer seeking one consolidated global contract, huge paid-media buying power or thousands of production hands may prefer a holding-company agency. A startup without a defensible specialty cannot imitate forty years of pattern recognition by declaring itself a boutique. And senior-led service stops being distinctive the moment growth pulls those senior people away from delivery.
MCS therefore occupies a precise place in the market. It is smaller than healthcare communications giants such as Real Chemistry, Inizio Evoke and the health practices of global networks. It is broader than a single-service science-writing studio. It competes on the claim that a compact, healthcare-only team can make better judgments, then borrow the reach required to carry those judgments around the world.
The firm's latest line is that healthcare PR has become insight-driven rather than channel-driven. That is a tidy description of its own forty-year arc. Newspapers gave way to websites, social platforms, influencers and AI summaries. The delivery machinery kept changing. The hard part did not: find the truth inside complicated science, locate the person who must understand it, and give that person a useful next move.
Keep reading
Explore the agency, its current thinking and the independent network behind its international reach.